

Ju.A. Popova, M.I. Krylova, V.N. Yadrinskaya, N.V. Borisova, P.G. Petrova, N.E. Kardashevskay

COMPARISON OF CLINICAL AND LABORATORY PARAMETERS IN PATIENTS WITH END-STAGE RENAL FAILURE IN THE OUTCOME OF CHRONIC GLOMERULONEPHRITIS AND OTHER DISEASES

ABSTRACT

Frequent complications of hemodialysis treatments are coagulation disorders. First of all, this is due to activation of the coagulation of blood flow in the interaction with a dialysis membrane material vascular prostheses and extracorporeal circuit trunks. In addition, in hemodialysis patients receiving heparin for years, there is depletion of stocks in endothelial cells in tissue factor inhibitor, inhibits the activity of an external blood clotting mechanism. To evaluate the hemostatic system parameters in patients with end-stage renal failure, depending on the cause of renal failure and hemodialysis treatment duration conducted a study that included 100 patients observed in the department of chronic hemodialysis and nephrology hospital №1 Republican National Medical Center in the period of 2013-2016. It was revealed that the state of homeostasis in patients with end-stage renal failure in increasingly characterizes the level of fibrinogen and the activation of the hemostatic markers: soluble fibrin monomer complexes, D-dimers. In patients with end-stage renal failure in the outcome of chronic glomerulonephritis, a great expression of activation of blood coagulation confirm increased the mean concentration of fibrinogen, whereas in the group, which included patients with end-stage renal failure in the outcome of other diseases (type 1 diabetes, type 2 diabetes, systemic disease, polycystic kidney disease, hypertensive nephroangiosclerosis, anomalies of development of kidneys, chronic pyelonephritis, urate nephropathy), such is not different from the norm, and a higher rate of hyperfibrinogenemia, identified in 2/3 patients in this group. 18 patients (18%) were diagnosed with thrombosis of arteriovenous fistula, 5 patients (5%) was revealed thrombosis of vessels of other organs and systems. There was found in patients bleeding and anemia associated with all erythropoietin deficiency.

Keywords: hemostasis, terminal renal failure, renal replacement therapy.

INTRODUCTION

In Russia, according to the Register of the Russian Dialysis Society, in 2013, 35305 people received various types of renal replacement therapy, the annual increase in the number of patients with an average of 12.4%. The average age of the patients in our country, receiving renal replacement therapy, is 47 years, the young, able-bodied part of the population greatly affected [2, 10]. Frequent complications of hemodialysis treatments are coagulation disorders. First of all, this is due to activation of the coagulation of blood flow in the interaction with a dialysis membrane material vascular prostheses and extracorporeal circuit trunks [1, 5]. In addition, in hemodialysis patients receiving heparin for years, there is depletion of stocks in endothelial cells in tissue factor inhibitor, inhibits the activity of an external blood clotting mechanism [4, 11].

The aim of our study was to evaluate the hemostatic system parameters in patients with end-stage renal failure, depending on the cause of renal failure.

MATERIALS AND METHODS

The study included 100 patients: 59 women (59%) and 41 men (41%) aged 19 to 79 years (middle age 46.5 ± 14.6 years) observed in the department of chronic hemodialysis and nephrology of Republican Hospital National medical center №1 in the period from 2013 to 2016. All the patients at the time of inclusion in the study were diagnosed

with end-stage renal disease (ESRD), which corresponded to the stage V chronic kidney disease (CKD), according to the criteria of clinical practice guidelines for CKD (KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease) by 2012 [10]. The cause of end-stage renal failure in most cases acts as chronic glomerulonephritis (CGN) - 43%, in second place (20%) - with diabetic nephropathy in type 2 diabetes [10].

The study was conducted in 2 phases: The purpose of Phase I was to find out what settings to change coagulation in patients with ESRD treated with hypertonia. In this part of the study included all patients who were treated in the department of chronic hemodialysis and nephrology hospital of Republican Hospital №1 - National Medical Center in the period from 2013 to 2016. The purpose of phase II study was to compare blood coagulation parameters in patients diagnosed with ESRD in the outcome of CGN, are on the program of the hemodialysis, and ESRD patients in the outcome of other diseases. 84 patients were included in this part of the study.

Inclusion criteria were: all patients diagnosed with a cause of ESRD treated with hypertonia. Exclusion criteria were: unknown cause of ESRD patient's refusal of the study.

The patients were divided into groups depending on the cause of ESRD: the outcome of the CGN or in the outcome

of other diseases (type 1 diabetes, type 2 diabetes mellitus, systemic disease, polycystic kidney disease, hypertensive nephroangiosclerosis, anomalies of development of kidneys, chronic pyelonephritis, urate nephropathy). Group A consisted of 43 patients (20 men and 23 women) aged 19 to 61 years (38 ± 10.5 years), diagnosed with ESRD in the outcome of chronic glomerulonephritis. In group B included 41 patients (15m: 26w) aged 22 to 79 years (57 ± 15 years), diagnosed with ESRD in the outcome of other diseases.

To describe the data X calculated average value and standard deviation (σ) of the studied parameters. Determination was carried out by Spearman correlation method. Authentic differences at $p < 0.05$ shall be deemed. All calculations were performed on a PC using SPSS 10 for Windows software packages.

RESULTS AND DISCUSSION

The following results were obtained by processing the data: 18 patients (18%) were diagnosed with thrombosis of arteriovenous fistula (AVF), 5 patients (5%) was revealed thrombosis of vessels of other organs and systems. Bleeding in patients was found, anemia associated with all erythropoietin deficiency [8, 9].

In the study a total level of blood platelets, it was found that the platelet count in the total group averaged $263 \pm 97.2 \times 10^9 / L$ (55 to $502 \times 10^9 / L$). Thrombocytopenia rate was 10%, thrombocytosis - 13%.

The study revealed coagulation parameters: thrombin time (TT) in patients ranged from 14.5 to 32.9 seconds (average 22.5 ± 4.6 seconds) at a rate of 16-26 seconds. Prothrombin Time Indicators (PT) - from 8.1 to 17.9 seconds (average 10.65 ± 2.45 seconds) at a rate 9-12,6 seconds. Prothrombin index (PTI) - from 59.58 to 396.14% (mean $116 \pm 40.2\%$) at normal rates 78-142%. The international normalized ratio (INR) of 0.75 to 1.34 (mean 0.9 ± 0.1), the norm: 0.81-1.13. Activated partial thromboplastin time (APTT) of 20 to 48.1 seconds (mean value of 30.2 ± 4.35 seconds) at a rate of 23,4-35 seconds. Fibrinogen level from 2.22 to 9.5 g / l (mean value of 5.0 ± 1.3 g / l) at a rate of 2-4 g / l.

A blood test for soluble fibrin monomer complex (SFMC) was taken in 26 patients, figures ranged from 4.5 to 26 mg% (mean 10 ± 6.3 mg%) at a rate of up to 4 mg%.

D-dimers were detected in 46% of patients ranged from indicators 0.34 to 1184 ng / mL (mean 230 ± 355.5 ng / ml) at a rate of less than 500 ng / ml [6, 7] (see the Table 1).

At the second stage of the study, we compared the patients with ESRD in the end of the CGN and the outcome of other diseases (of 84 people). Group A consisted of 43 patients (20m: 23w) aged 19 to 61 years (38 ± 10.5 years), diagnosed with ESRD in the outcome of chronic glomerulonephritis. In group B included 41 patients (15m: 26w) aged 22 to 79 years (57 ± 15 years), diagnosed with ESRD in the outcome of other diseases. From the study excluded 16 patients with unclear etiology of ESRD.

In both groups, the platelet count was almost the same. In group A platelet level averaged $276 \pm 103 \times 10^9 / L$ (range 61.2 to $502 \times 10^9 / L$). In group B - $265 \pm 98 \times 10^9 / L$ (55 to $495 \times 10^9 / L$). The frequency of thrombocytopenia and thrombocytosis was low and comparable in both groups (Table 2).

The average values of "routine" of hemostasis (TT, PT, INR, aPTT, PTI) did not deviate from the norm and were similar in both groups (Table 3).

In group A, the value of thrombin time in patients ranged from 14.5 to 32.9 sec, an average of 23.3 ± 4.8 sec. Shortening TT was observed in 3 patients, elongation - in 12. In group B thrombin time values in patients ranged from 16.3 to 31.8 sec, an average of 22 ± 4.8 sec. Shortening TT is not mentioned in any of the patient, TT elongation was 7 patients.

The values of the prothrombin time in group A patients ranged from 8.5 to 17 seconds, an average of 10 ± 2.45 seconds. Shortening PT was observed in 7 patients, elongation - in 15 patients. In group B prothrombin

time values in patients ranged from 8.1 to 17.9 seconds on average 10.9 ± 2.6 seconds. Shortening PT was observed in 6 patients, elongation - in 16 patients.

The values of the international normalized ratio in group A patients ranged from 0.77 to 1.2 seconds, on average 0.91 ± 0.1 seconds. Reducing the INR was observed in 5 patients, an increase - in 1 patient. In Group B patients INR values ranged from 0.75 to 1.28 seconds, on average 0.9 ± 0.1 seconds. Reducing the INR was observed in 5 patients, an increase - in 6 patients.

Values of activated partial thromboplastin time in Group A patients ranged from 20 to 39.9 seconds on average 30.2 ± 4.5 seconds. The shortening of the aPTT was observed in 4 patients, elongation - in 8 patients. In Group B patients APTT values ranged from 24.5 to 48.1 seconds on average 30.5 ± 4.4 seconds. The shortening of the aPTT is not mentioned, the extension - in 4 patients.

Prothrombin index values in group A patients ranged from 73 to 181.8%, with an average $128.6 \pm 27.2\%$. Reducing the PTI noted in 1 patient, increase - in 13 patients. In group B the values of prothrombin index in patients ranged from 68 to 396.14%, the average $109 \pm 53.2\%$. Reducing the PTI noted in 3 patients, an increase - in 9 patients.

Average levels of antithrombin III (AT III) were normal [3, 4] and did not differ

in both groups. In group A, the average level of AT III was $103.5 \pm 21.7\%$ (from 70 to 161.96%) in Group B - $104 \pm 21.1\%$ (from 82.92 to 134%). In this case more than 1/3 of the patients group B and up to 30% group A marked high values of AT III, exceeding the physiological rate.

In group A greater intensity of activation of blood clotting confirm increased the mean concentration of fibrinogen, whereas in group B such does not differ from the norm (cf. fibrinogen level in group B - 4.07 ± 1.6 g / l, group A - 5.09 ± 1.1 g / l ($p = 0.004$)), and a higher rate of hyperfibrinogenemia, identified in 2/3 patients in this group.

CONCLUSION

Thus, in group A ($n = 43$), which included those with ESRD in the outcome of CGN, lower figures of blood pressure were recorded than in group B ($n = 41$), which included patients with ESRD in the outcome of other diseases. In group A, patients with diagnosed hypertension accounted for 41.5%, in group B 61.4%.

Severity of anemia in patients with ESRD in the outcome of CGN was the same as that of untreated hemodialysis over a year. Patients in both groups did not differ ($P > 0.05$) in the levels of creatinine (865.2 ± 269 mmol / l in group A; 812.6 ± 226 mmol / l in group B.).

Thrombosis AVF in ESRD in the outcome CGN occurred in 7 patients in the outcome of other diseases of the kidneys - in 11 patients (in the outcome of

Table 1

Indicators of coagulation in the total group

Index	Norm values	The average		The middle value
		min	max	
TT	16-26	14,5	32,9	$22,5 \pm 4,6$
PT	9-12,6	8,1	17,9	$10,65 \pm 2,45$
IRN	0,81-1,13	0,75	1,34	$0,9 \pm 0,1$
APTT	23,4-35	20	48,1	$30,2 \pm 4,35$
Fibrinogen, g / l	2-4	2,22	9,5	$5 \pm 1,3$
PTI, %	78-142	59,58	396,14	$116 \pm 40,2$
SFMC	<4	4,5	26	$10 \pm 6,3$
D-dimer	<500	0,34	1184	$230 \pm 355,5$

Table 2

Frequency of thrombocytopenia in patients with ESRD in the outcome of CGN and patients with ESRD in the outcome of other diseases

Group	Уровень тромбоцитов, $\times 10^9 / L$		
	thrombocytopenia < $150 \times 10^9 / L$	Norma $150-400 \times 10^9 / L$	Thrombocytosis > $400 \times 10^9 / L$
A ($n=43$)	5 (11,6 %)	31 (72,1 %)	7 (16,3 %)
Б ($n=41$)	4 (9,8 %)	32 (78 %)	5 (12,2 %)

Note: $p > 0,004$ (between t A and t B).

Table 3

Group	Group A	Group B	Norma	p
TB, c	$23,3 \pm 4,8$	$22 \pm 4,8$	16-26	NS
ПВ, c	$10 \pm 2,45$	$10,9 \pm 2,6$	9-12,6	NS
МНО	$0,91 \pm 0,1$	$0,9 \pm 0,1$	0,81-1,13	NS
АЧТВ, c	$30,2 \pm 4,5$	$30,3 \pm 4,4$	23,4-35	NS
ПТИ, %	$128,6 \pm 27,2$	$109,4 \pm 53,2$	78-142	$p=0,03$

diabetic nephropathy in type 2 diabetes - 3, hypertensive nephroangiopathy - 3, systemic diseases - 1, polycystic kidney - 1, urate nephropathy 1).

Indicators of platelet hemostasis in both groups were similar (in grams. A $276 \pm 103 \times 109 / l$, c. B $265 \pm 98 \times 109 / l$). The frequency of thrombocytopenia and thrombocytosis was small and comparable in both groups.

The average values of "routine" of hemostasis (TT, PT, INR, aPTT, PTI) did not deviate from the norm and were similar in both groups.

In group A greater intensity of activation of blood coagulation confirm increased the mean concentration of fibrinogen, whereas in group B such does not differ from the norm (the average level of fibrinogen in g B - $4.07 \pm 1.6g / l$, g A - $5.09 \pm 1.1g / l$ ($p = 0.004$)), and a higher rate of hyperfibrinogenemia, identified in 2/3 patients in this group.

REFERENCES:

1. Barkagan Z.S., Momot A.P. Diagnostika i kontroliruyemaya terapiya narushenii gemostaza [Diagnosis and controlled therapy of hemostasis disorders]. Moscow: Nyudiamed, 2012, 165 p.
2. Bikbov B.T., Tomilina N.A. Zamestitelnaya terapiya terminalnoi khronicheskoi pochechnoi nedostatochnosti v Rossiiskoi Federatsii v 1998-2013. Otchet po dannym Rossiskogo registra zamestitelnoi pochechnoi terapii [Substitution treatment of terminal chronic renal failure to the Russian Federation Register of renal replacement therapy] Nefrologiya i dializ [Nephrology and Dialysis] • Annex to the V. 17, № 3, 2015.
3. Vorobyev P.A. Aktualnyi gemostaz [Actual hemostasis]. Moscow:

Nyudiamed, 2004, 140 p.

4. Vorobyov E.D. Rukovodstvo po gematologii [Manual Hematology]. Moscow: Nyudiamed, 2015, 216 p.

5. Zabolotskikh I.B., Sinkov S.V., Shaposhnikov S.A. Diagnostika i korrektsiya rasstroystv sistemy gemostaza [Diagnostics and correction of disorders of the hemostasis system] / Rukovodstvo dlya vrachei [guide for doctors] Prakticheskaya Meditsina, 2015, 16 July, 333.

6. Ilyin A.P., Bogojavlentsev V.F. Trombofiliya pri gemodialize u bolnykh khronicheskoi pochechnoi nedostatochnoty [Thrombophilia in hemodialysis patients with chronic renal failure] Posobiye dlya vrachei [manual for doctors], 2nd ed. Kazan: Kazan-pechat, 2011, 56 p.

7. Kozlov A.A. [et al.] Laboratornaya diagnostika sistemy gemostaza [Laboratory diagnosis of hemostasis]. Moscow: Litterra, 2011, 136 p.

8. Momot A.P. Patologiya gemostaza [Pathology of hemostasis]. St. Petersburg: Express, 2012, 210 p.

9. Suslov V. [et al.] Otsenka riska trombozov u bolnykh khronicheskoi pochechnoi nedostatochnostyu na etape dializnoi terapii [Assessment of risk of thrombosis in patients with chronic renal failure on dialysis stage] Sbornik: Tsitometriya v meditsine i biologii: fundamentalnyie i prikladnyie aspekty [Collection: Cytometry in medicine and biology: fundamental and applied aspects]. Moscow: RIALTEKS: 2008, p.56-57.

10. Smirnov A.V., Shilov E.M., Dobronravov V.A. Khronicheskaya bolezn pohek: osnovnye printsipy skrininga, diagnostiki i podkhody lecheniya: natsionalnyie rekomendatsii [Chronic kidney disease: the basic principles

of screening, diagnosis, prevention and treatment approaches: national guidelines]. Levsha, Saint Petersburg, 2012, 54p.

11. Gafter U., Bessler H., Malachi T. Platelet count and thrombopoietic activity in patients with chronic renal failure / Nephron. 2012. 45: 207-210.

The authors:

Popova Julia Alexeevna, graduate student, Medical Institute, "North-Eastern Federal University". Address: 677008, Republic of Sakha (Yakutia), Yakutsk, Kalandarishvili 38/5 sq. 27. Phone: 89142767120. E-mail: klausjuly@mail.ru;

Yadrihinskaya Vera Nikolaevna, Phypertinya, associate professor of "Hospital therapy, occupational diseases and clinical pharmacology Department", Medical Institute, "North-Eastern Federal University";

Krylova Maria Ivanovna, Phypertinya, senior lecturer of "Hospital therapy, occupational diseases and Clinical Pharmacology Department", Medical Institute, "North-Eastern Federal University";

Borisova Natalia Vladimirovna, professor of "Normal and pathology physiology Department", Medical Institute, "North-Eastern Federal University";

Petrova Palmira Georgievna, chief of "Normal and pathology physiology Department", Medical Institute, "North-Eastern Federal University";

Kardashevskaya Nadezhda Egorovna, 5th year student of the Medical Institute, «North-Eastern Federal University». Address: 677008, Republic of Sakha (Yakutia), Yakutsk, Lenina 56 sq. 9. Phone: 89243694511. E-mail: nadechek9437@gmail.com.

M.L. Khanzadyan, T.A. Demura, N.I. Duglas

GENETIC RISKS OF DEVELOPMENT OF PELVIC ORGAN PROLAPSE RECURRENCE AFTER HYSTERECTOMIES

ABSTRACT

Objective: to establish immunohistochemical and genetic markers of POP on the basis of studying of features of connecting tissue of women with a disease recurrence.

Materials and methods. The study involved 168 women, 134 of them with POP relapses aged 35 to 65 (96 after hysterectomy by vaginal access because of a total and partial uterus and vaginal walls prolapse). The control group consisted of 44 women aged 35-52 with no POP signs, after abdominal hysterectomy for uterine fibroids, adenomyosis, endometrial pathology.

Used: immunohistochemical (to assess tissue biopsies of sacrum-uterine and round uterine ligaments), the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs), genotyping by polymerase chain reaction of MMP/TIMP polymorphisms.

Results: Disturbances in the expression of the most important CT disorganization markers in POP shall comply with the expression of protein coding genes, in particular – MMPs and TIMP.

The results of studying the frequency of polymorphism genotypes in the groups of healthy women and those with POP are